Pharmacological bases of intraperitoneal chemotherapy;Bases pharmacologiques de la chimiothérapie intrapé ritonéale

Bulletin du Cancer

Volumn 96, Issue 12, 2009, Pages 1235-1242

  Gladieff, L ^a   Chatelut, E ^a   Dalenc, F ^a   Ferron, G ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Intraperitoneal chemotherapy; Ovarian adenocarcinoma; Pharmacology; Review

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID SOLUBILITY; MOLECULAR WEIGHT; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; PERITONEAL CAVITY; PERITONEUM; PHARMACOLOGICAL PARAMETERS; PLASMA CLEARANCE; REVIEW; TUMOR BLOOD FLOW; ANIMAL; ANIMAL MODEL; FEMALE; INFUSION; METABOLISM; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MOUSE; OVARY TUMOR; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MICE; MODELS, ANIMAL; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEUM;

EID: 74049092263     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0982     Document Type: Review

References (36)

1. Alberts D, Liu PY, Hannigan E, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 ; 335 : 1950-5.
2. Markman M, Bundy B, Alberts D, Fowler JM, Clark-Pearson DL, Carson L, et al. Phase III standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001 ; 19 : 1001-7.
3. Armstrong DK, Bundy BN, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 ; 354 : 34-43.
4. Rose PG, Piver S, Tsukada Y, Lau T. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989 ; 64 : 1508-13.
5. Dedrick RL, Myers CE, Bungay PM, deVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978 ; 62 : 1-11.
6. Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer 2008 ; 18 (Suppl 1) : 20-5.
7. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985 ; 3 (Suppl 4) : 38-42.
8. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, et al. Chemotherapy for murine ovarian cancer: a rationale for IP therapy with adriamycin. Cancer Treat Rep 1979 ; 63 : 269-73.
9. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol 1993 ; 14 : 15-28.
10. Howell SB, Chu BCF, Wung WE, Metha BM, Mendelsohn J. Long duration intracavitary infusion of methotrexate with systemic leucoverin protection in patients with malignant effusion. J Clin Invest 1981 ; 67 : 1161-70.
11. Howell SB, Pfeifle GL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982 ; 97 : 845-51.
12. Howell SB, Zimm S, Makman M, Abramson IS, Cleary S, Lucas WE, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987 ; 5 : 1607-12.
13. Piver SM, Lele SB, Manchetti DL. Surgically documented response to intraperitoneal cisplatin, cytarabine and bleomycin after intravenous cisplatin based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 1988 ; 6 : 1679-84.
14. Gitsch E, Sevelda P, Schimdl S, Salzer H. First experience with intraperitoneal chemotherapy in ovarian cancer. Eur J Gynecol Oncol 1990 ; 11 : 19-22.
15. Los G, Mutsaers HA, Van der Vijgh, Baldew GS, de Graaf PW, McVie GJ, et al. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989 ; 49 : 3380-4.
16. deForni M, Boneu A, Otal P, Martel P, Shubinski B, Bugat R, et al. Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography. Bull Cancer 1993 ; 80 : 345-50.
17. Neijt JP, ten Bokkel Huinnink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, et al. Randomised trial comparing two combination chemotherapy regimens (HexaCAF versus CHAP5) in advanced ovarian carcinoma. Lancet 1984 ; 2 : 594-600.
18. Rf O, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. Ann Int Med 1984 ; 100 : 19-24.
19. 2. Bull Cancer 1989 ; 76 : 879-82.
20. Gladieff L, Chatelut E, Gaspard MH, Skaf R, de Forni M, Mihura J, et al. Traitement de clôture des adénocarcinomes ovariens de stade avancé : étude pilote de chimiothérapie haute dose par voie intrapéritonéale. Bull Cancer 1999 ; 86 : 673-7.
21. Jandial DD, Farshchi-Heydari S, Larson C, Elliott G, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 2009 ; 15 : 553-60.
22. du Bois A, Lück J, Meier W, Adams HP, Möbus V, Costa S, et al. A randomised clinical trial of cisplatin-paclitaxel versus carboplatinpaclitaxel as first line treatment of ovarian cancer. J Nat Cancer Inst 2003 ; 95 : 1320-30.
23. Elferink F, van der Vigh WJF, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie G. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 1988 ; 21 : 57-60.
24. Los G, Verdegaal E, Mutsaers HA, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumors nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 1991 ; 28 : 159-66.
25. Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of nonsmall volume residual ovarian cancer. Gynecol Oncol 1993 ; 50 : 100-4.
26. Chatelut E, Canal P, Bugat R. Pharmacokinetics and individual dose-adjustment of carboplatin. Bull Cancer 2000 ; 87 (Spec) : 17-23.
27. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003 ; 90 : 637-43.
28. Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagoa S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal versus intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) Study. Gynecol Oncol 2005 ; 99 : 591-6.
29. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamidecisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003 ; 13 (Suppl 2) : 144-8.
30. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988 ; 48 : 4093-100.
31. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis Jr JL, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group Study. J Clin Oncol 1991 ; 10 : 1485-91.
32. Prudence F, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group Pilot Study. J Clin Oncol 1995 ; 13 : 2961-7.
33. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998 ; 16 : 2620-4.
34. Soma D, Kitayama J, Ishigami H, Kaisaki S, Nagawa H. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res 2009 ; 155 : 142-6.
35. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007 ; 13 : 2804-10.
36. Lu Z, Tsai M, Lu D, Wang J, Wientjes G, Au J. Tumorpenetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther 2008 ; 327 : 673-82.